Oncolytics Biotech Inc. (ONCY)

NASDAQ: ONCY · IEX Real-Time Price · USD
1.010
0.00 (0.00%)
Jun 24, 2024, 4:00 PM EDT - Market closed
0.00%
Market Cap 76.61M
Revenue (ttm) n/a
Net Income (ttm) -28.21M
Shares Out 75.85M
EPS (ttm) -0.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 87,506
Open 1.000
Previous Close 1.010
Day's Range 0.990 - 1.010
52-Week Range 0.880 - 3.370
Beta 1.40
Analysts Strong Buy
Price Target 4.33 (+328.71%)
Earnings Date May 9, 2024

About ONCY

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelare... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 8, 1999
Employees 29
Stock Exchange NASDAQ
Ticker Symbol ONCY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ONCY stock is "Strong Buy." The 12-month stock price forecast is $4.33, which is an increase of 328.71% from the latest price.

Price Target
$4.33
(328.71% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

Wayne Pisano, Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer study continues to be expected in H2 2024 Pelareorep combination ther...

11 hours ago - PRNewsWire

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer

Demonstrating pelareorep's synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients it may benefit Funding for the study comes from the US$5 million T...

4 days ago - PRNewsWire

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

Trial-in-progress abstract highlights new cohort that could expand the company's pancreatic cancer program Pelareorep's ability to expand TILs highlights its immunotherapeutic mechanism of action and ...

4 weeks ago - PRNewsWire

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

SAN DIEGO and CALGARY, AB , May 16, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announce...

5 weeks ago - PRNewsWire

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

Anticipated evaluation to include combination therapy featuring treatment regimen of checkpoint inhibition and chemotherapy utilized in cohort 1 of the GOBLET study GCAR is launching a new master prot...

5 weeks ago - PRNewsWire

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

Pelareorep advancing to registration-enabling studies Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- metastatic breast cancer Overall survival d...

6 weeks ago - PRNewsWire

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study Study of modified FOLFIRINOX/pelareorep/atezolizumab (Tecentriq®) combination expands existing pancreatic ...

6 weeks ago - PRNewsWire

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

SAN DIEGO and CALGARY, AB , May 8, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced...

6 weeks ago - PRNewsWire

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Conference call and webcast to take place on Thursday, May 9, 2024, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , April 30, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a lea...

7 weeks ago - PRNewsWire

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

SAN DIEGO and CALGARY, AB , April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announ...

2 months ago - PRNewsWire

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer Overall survival results from the randomized HR+/HER2- metastatic bre...

2 months ago - PRNewsWire

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

SAN DIEGO and CALGARY, AB , April 2, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that Pres...

2 months ago - PRNewsWire

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combination with mFOLFIRINOX Impressive objective response...

3 months ago - PRNewsWire

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - March 6, 2024) - Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on devel...

Other symbols: BLRXCADLIMRX
3 months ago - Newsfile Corp

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

US$5M grant supports study of pelareorep in combination with modified FOLFIRINOX +/- atezolizumab Testing with the most common therapies could facilitate broad use of pelareorep in pancreatic cancer p...

3 months ago - PRNewsWire

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Conference call and webcast to take place on Thursday, March 7, 2024, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , March 4, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a cl...

4 months ago - PRNewsWire

Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

SAN DIEGO and CALGARY, AB , Feb. 28, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that Chie...

4 months ago - PRNewsWire

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - February 15, 2024) - Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on c...

4 months ago - Newsfile Corp

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

Successful Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expansion SAN DIEGO and CALGARY, Alb...

4 months ago - PRNewsWire

Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors

SAN DIEGO and CALGARY, AB , Jan. 9, 2024 /PRNewswire/ --  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the appoi...

5 months ago - PRNewsWire

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

SAN DIEGO, CA and CALGARY, AB, Jan. 4, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, reported on significant...

6 months ago - PRNewsWire

Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS

Pelareorep induced prominent expansion of pre-existing Tumor Infiltrating Lymphocytes (TILs) in the blood and new TILs in the tumor Data highlights the association between the expansion of existing TI...

7 months ago - PRNewsWire

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, including a complete response SAN DIEGO and CALGARY, Alberta , Nov. 9, 2023 /PRNewswire...

8 months ago - PRNewsWire

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep

Updated plan follows PanCAN's strategic re-evaluation of the Precision PromiseSM Program PanCAN US$5 million grant provides support for new GOBLET mFOLFIRINOX arm to proceed as planned New Phase 3 str...

8 months ago - PRNewsWire

Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC

Novel imaging mass cytometry (IMC) technology enables a closer look at tumor microenvironment post-pelareorep/atezolizumab/letrozole treatment Affirms pelareorep's ability to increase PD-L1 positive c...

8 months ago - PRNewsWire